On December 24, Glonghui reported that the USA Food and Drug Administration (FDA) has revoked the emergency use authorization for four COVID-19 antibody drugs, including Eli Lilly and Co's bebtelovimab, AstraZeneca's Evusheld, GlaxoSmithKline's sotrovimab, and Regeneron's REGEN-COV. The FDA stated in a letter at the beginning of this month that the shelf life of these drugs has expired and that they have not been authorized for patients for more than a year due to the spread of non-susceptible variants. According to the FDA, the four companies mentioned do not intend to continue offering the relevant products in the USA, will notify customers and suppliers about the revocation of authorization, and will instruct how to destroy or return the products.